Clinical Trial Update: Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating daratumumab in combination with lenalidomide and dexamethasone in relapsed or relapsed-refractory multiple myeloma; results were post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)
• Decadron (Dexamethasone)
• Revlimid (lenalidomide)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-04-14